Search Results - "Fischer von Weikersthal, L."

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study by Stintzing, S, Miller-Phillips, L, Modest, D.P, Fischer von Weikersthal, L, Decker, T, Kiani, A, Vehling-Kaiser, U, Al-Batran, S.-E, Heintges, T, Kahl, C, Seipelt, G, Kullmann, F, Stauch, M, Scheithauer, W, Held, S, Moehler, M, Jagenburg, A, Kirchner, T, Jung, A, Heinemann, V

“…Abstract Background RAS and BRAF mutations have been identified as negative prognostic factors in metastatic colorectal cancer. Efficacy of 5-fluorouracil,…”
Get full text

Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the ‘burden of therapy’ method by Haas, M., Waldschmidt, D.T., Stahl, M., Reinacher-Schick, A., Freiberg-Richter, J., Fischer von Weikersthal, L., Kaiser, F., Kanzler, S., Frickhofen, N., Seufferlein, T., Dechow, T., Mahlberg, R., Malfertheiner, P., Illerhaus, G., Kubicka, S., Abdul-Ahad, A., Snijder, R., Kruger, S., Westphalen, C.B., Held, S., von Bergwelt-Baildon, M., Boeck, S., Heinemann, V.

“…Targeting the epidermal growth factor receptor pathway remains controversial in pancreatic cancer. Afatinib is an oral irreversible ErbB family blocker…”
Get full text

Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’ by Haas, M., Siveke, J.T., Schenk, M., Lerch, M.M., Caca, K., Freiberg-Richter, J., Fischer von Weikersthal, L., Kullmann, F., Reinacher-Schick, A., Fuchs, M., Kanzler, S., Kunzmann, V., Ettrich, T.J., Kruger, S., Westphalen, C.B., Held, S., Heinemann, V., Boeck, S.

“…In metastatic pancreatic ductal adenocarcinoma (mPDAC) treatment, erlotinib is known to be more effective in patients developing skin rash. Treatment with the…”
Get full text

Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study by Perkhofer, L, Berger, A W, Beutel, A K, Gallmeier, E, Angermeier, S, Fischer von Weikersthal, L, Goetze, T O, Muche, R, Seufferlein, T, Ettrich, T J

“…Biliary tract cancer (BTC) has a high mortality. Primary diagnosis is frequently delayed due to mostly unspecific symptoms, resulting in a high number of…”
Get full text

Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial) by Holch, J.W., Ricard, I., Stintzing, S., Fischer von Weikersthal, L., Decker, T., Kiani, A., Vehling-Kaiser, U., Heintges, T., Kahl, C., Kullmann, F., Scheithauer, W., Moehler, M., Jelas, I., Modest, D.P., Westphalen, C.B., von Einem, J.C., Michl, M., Heinemann, V.

“…Increased baseline carcinoembryonic antigen (CEA) serum level is associated with inferior overall survival (OS) in metastatic colorectal cancer (mCRC)…”
Get full text

Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306) by Modest, D.P., Ricard, I., Stintzing, S., Fischer von Weikersthal, L., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Kahl, C., Seipelt, G., Kullmann, F., Scheithauer, W., Moehler, M., Westphalen, C.B., Holch, J.W., von Einem, J.C., Held, S., Heinemann, V.

“…We explored the impacts of sequential application of various treatment lines on survival kinetics. Therefore, differences in overall survival (OS) observed in…”
Get full text

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial by Stintzing, S., Wirapati, P., Lenz, H.-J., Neureiter, D., Fischer von Weikersthal, L., Decker, T., Kiani, A., Kaiser, F., Al-Batran, S., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., Kullmann, F., Moehler, M., Scheithauer, W., Held, S., Modest, D.P., Jung, A., Kirchner, T., Aderka, D., Tejpar, S., Heinemann, V.

“…FIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) patients…”
Get full text

Resilience in cancer patients and how it correlates with demographics, psychological factors, and lifestyle by Festerling, Lara, Buentzel, J., Fischer von Weikersthal, L., Junghans, C., Zomorodbakhsch, B., Stoll, C., Prott, F.-J., Fuxius, S., Micke, O., Richter, A., Sallmann, D., Huebner, J., Hoppe, Catalina

“…Background Being diagnosed with cancer is challenging. Many patients wish to be actively involved in treatment and contribute to therapy, but the patients’…”
Get full text

Sense of coherence and its context with demographics, psychological aspects, lifestyle, complementary and alternative medicine and lay aetiology by Bargehr, B., Fischer von Weikersthal, L., Junghans, C., Zomorodbakhsch, B., Stoll, C., Prott, F.-J., Fuxius, S., Micke, O., Hübner, J., Büntzel, J., Hoppe, C.

“…Purpose For patients with a cancer diagnosis, coping abilities are of high importance. Cancer patients with a high sense of coherence may cope better. The…”
Get full text

Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306) by Holch, J.W., Held, S., Stintzing, S., Fischer von Weikersthal, L., Decker, T., Kiani, A., Kaiser, F., Heintges, T., Kahl, C., Kullmann, F., Scheithauer, W., Moehler, M., von Einem, J.C., Michl, M., Heinemann, V.

“…Cetuximab-induced skin toxicity (Cet-ST) is positively associated with outcome in metastatic colorectal cancer (mCRC). Besides its predictive relevance for…”
Get full text

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306 by Stintzing, S., Fischer von Weikersthal, L., Decker, T., Vehling-Kaiser, U., Jäger, E., Heintges, T., Stoll, C., Giessen, C., Modest, D.P., Neumann, J., Jung, A., Kirchner, T., Scheithauer, W., Heinemann, V.

“…The AIO KRK-0306 trial compares the efficacy of infusional 5-fluorouracil, folinic acid, irinotecan (FOLFIRI) plus cetuximab with FOLFIRI plus bevacizumab in…”
Get full text

Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer by Sommerhäuser, G, Kurreck, A, Stintzing, S, Heinemann, V, von Weikersthal, L Fischer, Dechow, T, Kaiser, F, Karthaus, M, Schwaner, I, Fuchs, M, König, A, Roderburg, C, Hoyer, I, Quante, M, Kiani, A, Fruehauf, S, Müller, L, Reinacher-Schick, A, Ettrich, T J, Stahler, A, Modest, D P

“…Initial systemic therapy for patients with metastatic colorectal cancer (mCRC) is usually based on two- or three-drug chemotherapy regimens with…”
Get full text

EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104 by Boeck, S, Jung, A, Laubender, R P, Neumann, J, Egg, R, Goritschan, C, Vehling-Kaiser, U, Winkelmann, C, Fischer von Weikersthal, L, Clemens, M R, Gauler, T C, Märten, A, Klein, S, Kojouharoff, G, Barner, M, Geissler, M, Greten, T F, Mansmann, U, Kirchner, T, Heinemann, V

“…Background: We aimed to identify molecular epidermal growth factor receptor (EGFR) tissue biomarkers in pancreatic cancer (PC) patients treated with the…”
Get full text

A German multicenter, randomized phase III trial comparing irinotecan–carboplatin with etoposide–carboplatin as first-line therapy for extensive-disease small-cell lung cancer by Schmittel, A., Sebastian, M., Fischer von Weikersthal, L., Martus, P., Gauler, T.C., Kaufmann, C., Hortig, P., Fischer, J.R., Link, H., Binder, D., Fischer, B., Caca, K., Eberhardt, W.E.E., Keilholz, U.

“…This trial was designed to prove superiority of irinotecan over etoposide combined with carboplatin in extensive-disease small-cell lung cancer. Patients were…”
Get full text

Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5‐FU/LV plus irinotecan or irinotecan plus oxaliplatin as first‐line treatment (FIRE 1‐trial) by Stahler, A., Heinemann, V., Giessen‐Jung, C., Crispin, A., Schalhorn, A., Stintzing, S., Fischer von Weikersthal, L., Vehling‐Kaiser, U., Stauch, M., Quietzsch, D., Held, S., von Einem, J.C., Holch, J., Neumann, J., Kirchner, T., Jung, A., Modest, D.P.

“…Our aim was to investigate the impact of EREG and AREG mRNA expression (by RT‐qPCR) in patients with metastatic colorectal cancer (mCRC). In addition,…”
Get full text

Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI by Alig, A.H.S., Modest, D.P., Stintzing, S., Heinrich, K., Geissler, M., Fischer von Weikersthal, L., Decker, T., Vehling-Kaiser, U., Held, S., Moosmann, N., Stahler, A., Tannapfel, A., Giessen-Jung, C., Jung, A., Weiss, L., Heinemann, V.

“…Primary tumor (PT) sidedness is an established prognostic marker in metastatic colorectal cancer (mCRC) and has a predictive impact on the efficacy of…”
Get full text

Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial by Giessen, C, Fischer von Weikersthal, L, Laubender, R P, Stintzing, S, Modest, D P, Schalhorn, A, Schulz, C, Heinemann, V

“…Background: Liver-limited disease (LLD) denotes a specific subgroup of metastatic colorectal cancer (mCRC) patients. Patients and Methods: A total of 479…”
Get full text

A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer by Schmittel, A., von Weikersthal, L. Fischer, Sebastian, M., Martus, P., Schulze, K., Hortig, P., Reeb, M., Thiel, E., Keilholz, U.

“…Background: Superiority of irinotecan/cisplatin over etoposide/cisplatin was suggested in small-cell lung cancer (SCLC). This trial investigated…”
Get full text

Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial by Stintzing, S, Fischer von Weikersthal, L, Vehling-Kaiser, U, Stauch, M, Hass, H G, Dietzfelbinger, H, Oruzio, D, Klein, S, Zellmann, K, Decker, T, Schulze, M, Abenhardt, W, Puchtler, G, Kappauf, H, Mittermüller, J, Haberl, C, Giessen, C, Moosmann, N, Heinemann, V

“…Background: The AIO KRK-0104 randomised phase II trial investigated the efficacy and safety of two capecitabine-based regimens: combination of capecitabine and…”
Get full text

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial by von Einem, J. C., Heinemann, V., von Weikersthal, L. Fischer, Vehling-Kaiser, U., Stauch, M., Hass, H. G., Decker, T., Klein, S., Held, S., Jung, A., Kirchner, T., Haas, M., Holch, J., Michl, M., Aubele, P., Boeck, S., Schulz, C., Giessen, C., Stintzing, S., Modest, D. P.

“…Purpose AIO KRK-0104 investigated first-line therapy of metastatic colorectal cancer (mCRC) with cetuximab, capecitabine and irinotecan versus cetuximab,…”
Get full text